Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer.

Current medicinal chemistry - 1 Jan 2021

Niloy Mahruba Sultana, Shakil Md Salman, Alif Md Meharab Hassan, Rosengren Rhonda J

Abstract excerpt

Approximately 85% of all lungs cancer cases are classified as non-small cell lung cancer (NSCLC). Kirsten rat sarcoma (KRAS) viral oncogene homolog mutations frequently occur in NSCLC patients resulting in a decreased overall survival. Additionally, currently used chemotherapeutic drugs lack selectivity,and patients experience side effects. Therefore, potent therapeutic agents are urgently needed for these...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell Proliferation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Proto-Oncogene Proteins p21(ras)

Share to Signal Transduction

Source

Identifiers

PMID: 33645474
DOI: 10.2174/0929867328666210301105856

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Using Natural Compounds to Target KRAS Mutated Non-Small Cell Lung Cancer.PMID 33645474Read ↗

Targeting KRAS-mutant non-small cell lung cancer: challenges and opportunities.Semantic proximity Read ↗

First-line treatments for KRAS-mutant non-small cell lung cancer: current state and future perspectives.Semantic proximity Read ↗

Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.Semantic proximity Read ↗

Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Kirsten rat sarcoma inhibitors in clinical development against nonsmall cell lung cancer.Semantic proximity Read ↗

Targeting KRASG12D mutation in non-small cell lung cancer: molecular mechanisms and therapeutic potential.Semantic proximity Read ↗

Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.Semantic proximity Read ↗

Cutting edge therapies: A review of Food and Drug Administration-approved drugs for non-small cell lung cancer.Semantic proximity Read ↗

VT204: A Potential Small Molecule Inhibitor Targeting KRASG12C Mutation for Therapeutic Intervention in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.Semantic proximity Read ↗

Rosmarinic acid inhibits non-small cell lung cancer progression by directly targeting KRASG12C and modulating the KRAS/AKT/ERK signaling axis.Semantic proximity Read ↗

[Current status and outlook of medical treatment for KRAS-mutated non-small cell lung cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.